Atilotrelvir (development code GST-HG171) is a drug for the treatment of COVID-19.

[1][2] It has broad-spectrum anti-SARS-CoV-2 activity against different variants (including WT, β, δ, and omicron).

[3] In combination with ritonavir, it was approved for use in China in 2023.

[4] This antiinfective drug article is a stub.

You can help Wikipedia by expanding it.